Gesticare DHA Multi-Vitamin/Mineral Tablets
Product Type
Packaging Size
Serving Size
1.0 Tablet(s)
UPC
318860253307
Ingredients
Description
GDHA1-11-04 GDHA1-11-03 NDC 18860-253-30 (30 count)
6 blister cards; each containing 5 tablets and 5 capsules Not for Sale - Rx Only PHYSICIAN'S SAMPLES (NDC 18860-253-00) Contains 6 Patient Starter packages, each containing 2 tablets and 2 capsules
Formulation
Prenatal Multi-vitamin/Mineral Tablets with DHA and Choline Prenatal Multi-vitamin/Mineral Tablets with DHA and Choline Indications and Usage: Gesticare(R) DHA is indicated to provide vitamin/mineral and DHA omega-3 fatty acid supplement to women throughout pregnancy, during the postnatal period for both lactating and non-lactating mothers, and throughout the childbearing years. Gesticare(R) DHA may be beneficial in improving the nutritional status of women prior to conception.
Precautions
Do not use if blister seal is broken. Warnings: Ingestion of more than 3 grams of omega-3 fatty acids per day has been shown to have potential antithrombotic effects, including increased bleeding time and INR. Administration of omega-3 fatty acids should be avoided in patients on anticoagulants and in those known to have an inherited or acquired bleeding diathesis. Contraindications: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.
KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Administration of omega-3 fatty acids should be avoided in patients on anticoagulants and in those known to have an inherited or acquired bleeding diathesis. Precautions: Folic acid in doses above 0.1mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive. Adverse Reactions: Allergic sensitization has been reported following both oral and parenteral administration of folic acid.